NCT05892354 is a NA clinical trial of Enteral immunonutrition in Locally Advanced Nasopharyngeal Carcinoma, sponsored by First Affiliated Hospital of Guangxi Medical University.

Who is sponsoring NCT05892354?

NCT05892354 is sponsored by First Affiliated Hospital of Guangxi Medical University.

What drugs are being tested in NCT05892354?

Interventions in NCT05892354: Enteral immunonutrition, Standard enteral nutrition.

What condition does NCT05892354 study?

NCT05892354 studies Locally Advanced Nasopharyngeal Carcinoma.

Is NCT05892354 still recruiting?

NCT05892354 is currently recruiting now. Last updated 7 August 2024.

Last reviewed 2024-08-07 · How we verify

NCT05892354

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy

Recruiting now NA Last updated 7 August 2024

What this trial tests

NA trial testing Enteral immunonutrition in Locally Advanced Nasopharyngeal Carcinoma in 190 participants. Currently enrolling.

Timeline

12 June 2023

Primary endpoint
30 April 2025

1 April 2027

Quick facts

Lead sponsor	First Affiliated Hospital of Guangxi Medical University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	190
Start date	12 June 2023
Primary completion	30 April 2025
Estimated completion	1 April 2027
Sites	20 locations across China

Drugs / interventions tested

Enteral immunonutrition
Standard enteral nutrition

Conditions studied

Locally Advanced Nasopharyngeal Carcinoma — all drugs for Locally Advanced Nasopharyngeal Carcinoma →

Sponsor

First Affiliated Hospital of Guangxi Medical University

Who can join

Adults 18 to 70, any sex, with Locally Advanced Nasopharyngeal Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study was to investigate the role of immunonutrion compared with standard nutrition in reducing oral mucositis in patients with locally advanced nasopharyngeal carcinoma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Nutritional status, immunonutrition, and gut microbiome: a coming of age for immunotherapy?
Mattavelli E, Agustoni F, Tartara A, De Simeis F, et al · · 2025 · cited 3× · PMID 40927712 · DOI 10.3389/fimmu.2025.1612567

Verify or expand the search:

Other recruiting trials for Locally Advanced Nasopharyngeal Carcinoma

Currently open trials in the same condition.

NCT07085234 — Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC · Phase 2 · recruiting
NCT05397769 — Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial. · Phase 2 · recruiting
NCT05062005 — ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma · Phase 3 · recruiting

Other First Affiliated Hospital of Guangxi Medical University trials

Trials by the same sponsor.

NCT07459296 — Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC · Phase 3 · recruiting
NCT07342322 — A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatial · Phase 2 · not yet recruiting
NCT07338357 — Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML · EARLY_PHASE1 · not yet recruiting
NCT07132008 — Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer · Phase 3 · not yet recruiting
NCT07074444 — Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05892354 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Guangxi Medical University
Last refreshed: 7 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05892354.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing